BioXcel Therapeutics Inc (NASDAQ:BTAI) had its Buy rating reiterated by HC Wainwright with a $25.00 price target

Analyst Ratings For BioXcel Therapeutics Inc (NASDAQ:BTAI)

Story continues below

Today, HC Wainwright reiterated its Buy rating on BioXcel Therapeutics Inc (NASDAQ:BTAI) with a price target of $25.00.

There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on BioXcel Therapeutics Inc (NASDAQ:BTAI) is Buy with a consensus target price of $20.40 per share, a potential 339.66% upside.

Some recent analyst ratings include

  • 12/12/2018-BioXcel Therapeutics Inc (NASDAQ:BTAI) had its Buy rating reiterated by HC Wainwright with a $25.00 price target
  • 8/10/2018-BioXcel Therapeutics Inc (NASDAQ:BTAI) had its Buy rating reiterated by Canaccord Genuity with a $21.00 price target
  • 4/2/2018-BioXcel Therapeutics Inc (NASDAQ:BTAI) has coverage initiated with a Outperform rating and $23.00 price target
  • 4/2/2018-BioXcel Therapeutics Inc (NASDAQ:BTAI) has coverage initiated with a Buy rating and $18.00 price target
  • 4/2/2018-BioXcel Therapeutics Inc (NASDAQ:BTAI) has coverage initiated with a Overweight ➝ Overweight rating and $15.00 price target


    About BioXcel Therapeutics Inc (NASDAQ:BTAI)
    BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is headquartered in Branford, Connecticut. It has clinical partnership with Nektar Therapeutics. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.

    Recent Trading Activity for BioXcel Therapeutics Inc (NASDAQ:BTAI)
    Shares of BioXcel Therapeutics Inc closed the previous trading session at 4,62 +0,070 1,54 % with 4.81 shares trading hands.

    An ad to help with our costs